Real-World First-Line Use of Pertuzumab With Different Taxanes for Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer: A Comparative Effectiveness Study Using US Electronic Health Records

On the basis of the results from CLEOPATRA, pertuzumab plus trastuzumab and chemotherapy is the first-line standard of care for human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer (MBC). However, discrepancies have been reported between clinical trial and real-world out...

Descripción completa

Detalles Bibliográficos
Autores principales: Polito, Letizia, Shim, Jinjoo, Hurvitz, Sara A., Dang, Chau T., Knott, Adam, Du Toit, Yolande, Restuccia, Eleonora, Sanglier, Thibaut, Swain, Sandra M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2023
Materias:
ORIGINAL REPORTS
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10337715/
https://www.ncbi.nlm.nih.gov/pubmed/37167571
http://dx.doi.org/10.1200/OP.22.00565

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10337715/
https://www.ncbi.nlm.nih.gov/pubmed/37167571
http://dx.doi.org/10.1200/OP.22.00565

Ejemplares similares